Safety and tolerability of new-generation anti-obesity medications: a narrative review

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Postgraduate medicine

• Publication date

  2018-02-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/00325481.2018.1435129PMID 29388462PMCID PMC6261426
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

  2017influential reference
• The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: A multi-center study.

  2017cited by this paper
• Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release

  2017influential reference
• Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program

  2017cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016cited by this paper
• The Current Role of Liraglutide in the Pharmacotherapy of Obesity.

  2016cited by this paper
• Are healthcare costs from obesity associated with body mass index, comorbidity or depression? Cohort study using electronic health records

  2016cited by this paper
• Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.

  2016influential reference
• AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.

  2016cited by this paper
• Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

  2016cited by this paper
• Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trials

  2016cited by this paper
• Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents

  2016cited by this paper
• Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s

  2016cited by this paper
• Through Thick and Thin: Identifying Barriers to Bariatric Surgery, Weight Loss Maintenance, and Tailoring Obesity Treatment for the Future

  2016cited by this paper
• Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

  2015cited by this paper
• Pharmacotherapy for the management of obesity.

  2015cited by this paper
• Comorbidity associated with obesity in a large population: The APNA study.

  2015cited by this paper
• Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk

  2015cited by this paper
• Why do we need observational studies of everyday patients in the real-life setting?

  2015cited by this paper
• Safety and tolerability of medications approved for chronic weight management

  2015cited by this paper
• Prevalence of Obesity Among Adults and Youth: United States, 2011-2014.

  2015cited by this paper
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

  2015cited by this paper
• AHA / ACC / TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines and The Obesity Society Endorsed

  2014cited by this paper
• 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.

  2014cited by this paper
• Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

  2014cited by this paper
• Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

  2014cited by this paper
• Update on obesity pharmacotherapy

  2014cited by this paper
• Long-term drug treatment for obesity: a systematic and clinical review.

  2014cited by this paper
• Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease

  2014cited by this paper
• Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery

  2014influential reference
• Safety of antiobesity drugs

  2013cited by this paper
• Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

  2013cited by this paper
• Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults

  2013cited by this paper
• Elevated body mass index as a causal risk factor for symptomatic gallstone disease: A Mendelian randomization study

  2013cited by this paper
• Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

  2013cited by this paper
• Use of Prescription Antiobesity Drugs in the United States

  2013cited by this paper
• Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes.

  2013influential reference
• A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)

  2013cited by this paper
• Risk of colorectal cancer after initiation of orlistat: matched cohort study

  2013cited by this paper
• Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study

  2013cited by this paper
• A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.

  2012cited by this paper
• Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study

  2012cited by this paper
• Obesity and severe obesity forecasts through 2030.

  2012cited by this paper
• Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus

  2012cited by this paper
• Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

  2012cited by this paper
• GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

  2012cited by this paper
• Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

  2011cited by this paper
• Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial

  2011cited by this paper
• Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

  2011cited by this paper
• Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

  2011influential reference
• A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

  2011cited by this paper
• Body mass index and the risk and prognosis of acute pancreatitis: a meta-analysis

  2011cited by this paper
• Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

  2011cited by this paper
• Multicenter, placebo-controlled trial of lorcaserin for weight management.

  2010cited by this paper
• Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

  2010cited by this paper
• Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2010cited by this paper
• Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

  2010cited by this paper
• The Medical Risks of Obesity

  2009cited by this paper
• Annual medical spending attributable to obesity: payer-and service-specific estimates.

  2009cited by this paper
• Perioperative safety in the longitudinal assessment of bariatric surgery.

  2009cited by this paper
• Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

  2009influential reference
• A proposed clinical staging system for obesity

  2009cited by this paper
• Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

  2007cited by this paper
• Cholesterol gallstone disease.

  2006cited by this paper
• The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen.

  2006cited by this paper
• Long-term weight loss after diet and exercise: a systematic review

  2005influential reference
• XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

  2004cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• The Medical Risks of Obesity

  2002cited by this paper
• Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications

  2000cited by this paper
• Valvular heart disease associated with fenfluramine-phentermine.

  1997cited by this paper
• Pharmacotherapy in the management of obesity.

  1997cited by this paper
• Valvular heart disease associated with fenfluramine-phentermine.

  1997cited by this paper
• Available From

  1973cited by this paper

• The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome

  2026cites this paper
• Logistics, effectiveness, safety, and accessibility: Factors determining obesity medication patient preferences from a photovoice analysis.

  2025cites this paper
• Comprehensive review of bioactive compounds from microalgae as promising source for industrial applications

  2025cites this paper
• Obesity and Metabolic Syndrome: Current Insights and Future Directions.

  2025cites this paper
• Should Military Aircrew Members be Allowed to Use Food and Drug Administration Approved Weight Loss Medications? A Review of the Literature and Recommendations.

  2025cites this paper
• Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis.

  2025cites this paper
• Efficacy of Naltrexone/Bupropion in Treatment of Binge Eating: A Systematic Review and Meta-Analysis

  2024cites this paper
• What is the evidence regarding the safety of new obesity pharmacotherapies

  2024influential citation
• Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)

  2024cites this paper
• Biaryl carboxamide‐based peptidomimetics analogs as potential pancreatic lipase inhibitors for treating obesity

  2024cites this paper
• Dose‐dependent effects of anthocyanin‐rich extracts on obesity‐induced inflammation and gut microbiota modulation

  2024cites this paper
• Novel Therapeutic Approach for Obesity: Seaweeds as an Alternative Medicine with the Latest Conventional Therapy

  2024cites this paper
• The Definition and Prevalence of Obesity and Metabolic Syndrome: Correlative Clinical Evaluation Based on Phenotypes.

  2024cites this paper
• Pharmacotherapy of obesity: State of the art and perspectives

  2024cites this paper
• Potential contributors to variation in weight‐loss response to liraglutide

  2023cites this paper
• Medikamentöse Therapie der Adipositas – Konkurrenz zur bariatrischen Chirurgie oder sinnvolle Ergänzung?

  2023cites this paper
• Title: An analogue of the Prolactin Releasing Peptide reduces obesity and promotes adult neurogenesis Authors:

  2023influential citation
• Shedding light on weight loss: A narrative review of medications for treating obesity

  2023cites this paper
• Pharmacotherapy of Obesity: An Updated Overview

  2023cites this paper
• Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease

  2023cites this paper
• EXIST: EXamining rIsk of excesS adiposiTy—Machine learning to predict obesity‐related complications

  2023cites this paper
• Helichrysum stoechas (L.) Moench reduces body weight gain and modulates mood disorders via inhibition of silent information regulator 1 (SIRT1) by arzanol

  2023cites this paper
• Pharmacotherapeutics efficacy in obesity treatment: A systematic review

  2023cites this paper
• The treatment of obesity in children and adolescents: consensus position statement of the Italian society of pediatric endocrinology and diabetology, Italian Society of Pediatrics and Italian Society of Pediatric Surgery

  2023cites this paper
• Positive effects of dietary supplementation with nutraceuticals on male subclinical hypogonadism: a pilot study.

  2023cites this paper
• Current pharmacological approaches in obesity treatment

  2023cites this paper
• Combination of Lactobacillus plantarum HAC03 and Garcinia cambogia Has a Significant Anti-Obesity Effect in Diet-Induced Obesity Mice

  2023cites this paper
• Micronutrient Deficiency in Children and Adolescents with Obesity—A Narrative Review

  2023cites this paper
• An analogue of the Prolactin Releasing Peptide reduces obesity and promotes adult neurogenesis

  2023cites this paper
• Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity

  2023cites this paper
• Comparing and contrasting different herbal products intended for the management of obesity approved in the Palestinian markets

  2023cites this paper
• Effects of the Probiotic Lactiplantibacillus plantarum KU15120 Derived from Korean Homemade Diced-Radish Kimchi Against Oxidation and Adipogenesis

  2022cites this paper
• The effects and side effects of liraglutide as a treatment for obesity

  2022cites this paper
• Piperine attenuates hepatic steatosis and insulin resistance in high-fat diet-induced obesity in Sprague-Dawley rats.

  2022cites this paper
• Efficacy of Medical Weight Loss in the Cosmetic Surgery Practice

  2022cites this paper
• Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Medical treatment of weight loss in children and adolescents with obesity.

  2022cites this paper
• Parental Perceptions of Medication Use for the Treatment of Obesity in Youth

  2022cites this paper
• VLCKD: a real time safety study in obesity

  2022influential citation
• Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review

  2022cites this paper
• A narrative review of anti-obesity medications for obese patients with osteoarthritis

  2022cites this paper
• Quality of information on weight loss drugs from South American websites

  2022cites this paper
• Liraglutide Overdose-Induced Acute Pancreatitis

  2022cites this paper
• Cardiovascular Safety and Superiority of Anti-Obesity Medications

  2021cites this paper
• Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?

  2021cites this paper
• Targeting Autophagy to Counteract Obesity-Associated Oxidative Stress

  2021cites this paper
• Phenotypic Discovery of SB1501, an Anti‐obesity Agent, through Modulating Mitochondrial Activity

  2021cites this paper
• Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists

  2021cites this paper
• European Guidelines for Obesity Management in Adults with a Very Low-Calorie Ketogenic Diet: A Systematic Review and Meta-Analysis

  2021cites this paper
• Weight regulation in menopause

  2021cites this paper
• Bariatric Surgery in Adolescents: To Do or Not to Do?

  2021cites this paper
• Glucagon‐Like Peptide‐1 Receptor Activators

  2021cites this paper
• Patient initiation and maintenance of GLP-1 RAs for treatment of obesity

  2021cites this paper
• Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies.

  2021cites this paper
• Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020

  2021cites this paper
• Novel role of xanthine oxidase-dependent H2O2 production in 12/15-lipoxygenase-mediated de novo lipogenesis, triglyceride biosynthesis and weight gain

  2021cites this paper
• Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016.

  2021cites this paper
• Effect of Allium sativum extract in combination -with orlistat on insulin resistance and disrupted metabolic hormones in high fat diet induced obese rats

  2021cites this paper
• Anti-Obesity Activity of Polyherbal Formulation Divya-Medohar-Vati by Inhibition of Pancreatic Lipase Activity and Triglyceride Translocation through Enterocytes

  2021cites this paper
• Rhubarb hydroxyanthraquinones act as antiobesity agents to inhibit adipogenesis and enhance lipolysis.

  2021cites this paper
• Obesity in A Claims-Based Analysis of the Commercially Insured Population: Prevalence, Cost, and the Influence of Obesity Services and Anti-Obesity Medication Coverage on Health Expenditures

  2021cites this paper
• The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic ß-cell function in overweight/obese men: a single-arm uncontrolled study

  2020cites this paper
• Tinospora cordifolia ameliorates brain functions impairments associated with high fat diet induced obesity.

  2020cites this paper
• Very low-calorie ketogenic diet (VLCKD): indicazioni ed efficacia nel trattamento dell’obesità

  2020cites this paper
• Pharmacotherapy in pediatric obesity: current evidence and landscape.

  2020cites this paper
• Total Synthesis of Bisabolene Derivatives from the Marine Sponge Myrmekioderma sp.

  2020cites this paper
• Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers

  2020cites this paper
• Flavonoids as antiobesity agents: A review

  2020cites this paper
• VITAL POTENTIAL OF MULTIPLE HERBS IN PROPHYLAXIS OF OBESITY

  2020cites this paper
• Very low calorie ketogenic diets in overweight and obesity treatment: Effects on anthropometric parameters, body composition, satiety, lipid profile and microbiota.

  2020cites this paper
• New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.

  2020cites this paper
• Myo-inositol and D-chiro-inositol oral supplementation ameliorate cardiac dysfunction and remodeling in a mouse model of diet-induced obesity.

  2020cites this paper
• Medications for the treatment of obesity in adolescents

  2020cites this paper
• P2Y2 Receptor Promotes High-Fat Diet-Induced Obesity

  2020cites this paper
• An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder

  2020cites this paper
• Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review

  2020influential citation
• Obesity and gender differences

  2020cites this paper
• The cardiovascular safety of antiobesity drugs—analysis of signals in the FDA Adverse Event Report System Database

  2020cites this paper
• Liraglutide overdose: A case report and an updated review

  2020cites this paper
• Pharmacological Treatment for Obesity in Adults: An Umbrella Review

  2020cites this paper
• Anti-Obesity Effects of Microalgae

  2020cites this paper
• Anti-Obesity of Dried Mulberry Fruit Powder in Mice Fed with High-Fat Diet

  2020cites this paper
• Obesity and schizophrenia: New drugs, new hopes

  2020cites this paper
• Drug Pipeline for Obesity Therapy

  2020cites this paper
• ASSESSMENT OF THE EFFECTS OF STEADY-STATE BUPROPION ON THE PHARMACOKINETIC PROFILE OF ZOLPIDEM IN HEALTHY VOLUNTEERS

  2019cites this paper
• Preclinical and Clinical Evidence for a Distinct Regulation of Mu Opioid and Type 1 Cannabinoid Receptor Genes Expression in Obesity

  2019cites this paper
• Current Options for the Pharmacotherapy of Obesity.

  2019cites this paper
• Evidence-Based Cardiovascular Risk Management in Diabetes

  2019cites this paper
• THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE.

  2019cites this paper
• Current Treatments on Obesity

  2019cites this paper
• Topiramate And Phentermine

  2019cites this paper
• Anti-Obesity Effects of Microalgae

  2019cites this paper
• The Role of Bariatric Surgery on Diabetes and Diabetic Care Compliance

  2019cites this paper
• The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide

  2019cites this paper
• GEOFFREY HARRIS PRIZE LECTURE 2018: Novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans.

  2019cites this paper
• Pharmacotherapy of obesity: Available medications and drugs under investigation.

  2019cites this paper
• Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery

  2019cites this paper
• Houm Plant Extract (Ephedra), An Iranian Traditional Remedy for Insulin Resistance

  2019cites this paper
• Adipose tissue as a possible therapeutic target for polyphenols: A case for Cyclopia extracts as anti-obesity nutraceuticals.

  2019cites this paper
• ReviewAnti-Obesity Effects of MicroalgaeSaioa Gómez-Zorita 1

  2019cites this paper